The Long Case for Boston Scientific


The Long Case for Boston Scientific

Related Stocks: BSX Newsletter Value Investor Insight carried an interview May 30th with Troy Capital's Alex Troy, whose fund has returned an average of 23.6% annually net of fees since inception in March 2003, versus 15.8% for the S&P 500, according to Value Investor Insight. Here's the excerpt from the interview in which he discusses Boston Scientific (BSX), which was trading at $15.43 at the time of the interview (current price here): Complete Story »

You might be interested in these entries too:

Boston Scientific Backs Neuromodulation Technology Firm

Related Stocks: BSX Sara Calabro submits: Intelect Medical, an early stage Cleveland, OH, company...

Monday Market Rap: JSDA, BSX, ABT, AAPL & DNDN

Filed under: After the bell, Major movement, Apple Inc (AAPL), General Motors (GM), Abbott Laboratories (ABT), Boston Scientific (BSX), Jones Soda (JSDA), OptionsThe markets started the day in...

Responses to 'The Long Case for Boston Scientific'


  1. No Comments

Leave a Reply





eXTReMe Tracker